21 completed, 6 recruiting, 3 unknown, 2 active not recruiting. 13 Phase 2, 10 Phase 3, 3 Not applicable, 2 Phase 4.
Follow Hellenic Institute for the Study of Sepsis: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL Meropenem Infusion, Sodium Chloride (NaCl) 0.9 % - Sepsis | Phase 3 | Recruiting | Hellenic Institute for the Study of Sepsis | 398 | 2026-10-01 | 2026-10-19 |
| CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL Placebo, clarithromycin - Sepsis | Phase 3 | Recruiting | Hellenic Institute for the Study of Sepsis | 252 | 2026-09-01 | 2026-10-16 |
| Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial) Emapalumab-Izsg, Placebo - Sepsis | Phase 2 | Active not recruiting | Hellenic Institute for the Study of Sepsis | 75 | 2025-03-22 | 2025-11-19 |
| The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19 Blood samples, Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms - Pulmonary Complications, Cardiovascular Complications | Recruiting | Hellenic Institute for the Study of Sepsis | 345 | 2024-12-10 | 2025-11-17 | |
| Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. Blood samples and Oropharyngeal swab, Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms - Pneumonia, Community-Acquired, COVID-19 Pneumonia | Recruiting | Hellenic Institute for the Study of Sepsis | 650 | 2024-11-08 | 2026-07-06 | |
| Viscoelastic Coagulation for Early Sepsis Detection Viscoelastic Coagulation Monitoring measurements - Infection, Sepsis | Completed | Hellenic Institute for the Study of Sepsis | 147 | 2024-10-31 | 2026-09-21 | |
| Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) Clarithromycin 500mg, Tablets - Community-acquired Pneumonia | Phase 3 | Recruiting | Hellenic Institute for the Study of Sepsis | 330 | 2024-02-12 | 2025-12-16 |
| NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification NGS-based assay for bacterial identification - Pneumonia, Acute Pyelonephritis | Completed | Hellenic Institute for the Study of Sepsis | 100 | 2023-11-16 | 2024-03-29 | |
| Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial) Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results., Standard of Care - Sepsis | Phase 3 | Active not recruiting | Hellenic Institute for the Study of Sepsis | 190 | 2023-09-19 | 2026-01-16 |
| Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome Placebo, Anakinra 149 MG/ML Prefilled Syringe [Kineret] - Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 | Phase 2 / Phase 3 | Recruiting | Hellenic Institute for the Study of Sepsis | 182 | 2023-09-06 | 2026-01-08 |
| Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO MeMed BV® - Viral Infection, Bacterial Infections | Completed | Hellenic Institute for the Study of Sepsis | 230 | 2023-05-29 | 2024-03-06 | |
| Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia Anakinra Prefilled Syringe, Placebo - Community-acquired Pneumonia, Hospital-acquired Pneumonia | Phase 2 | Completed | Hellenic Institute for the Study of Sepsis | 60 | 2023-03-06 | 2024-07-31 |
| Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection Bezlotoxumab, Normal saline 0.9% or 5% dextrose water - Clostridioides Difficile Infection, Stool Microbiome | Phase 2 | Completed | Hellenic Institute for the Study of Sepsis | 44 | 2022-04-13 | 2026-03-04 |
| STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care Sodium Thiosulfate 25% Solution for Injection - COVID-19, Virus Diseases | Phase 2 | Unknown | Hellenic Institute for the Study of Sepsis | 30 | 2022-04-01 | 2023-01-13 |
| Personalized Immunotherapy in Sepsis Anakinra or rhIFNγ, Placebo - Sepsis | Phase 2 | Completed | Hellenic Institute for the Study of Sepsis | 280 | 2021-07-29 | 2025-03-19 |
| Addressing Personalized Needs in Clostridioides Difficile Infection Microbiome analysis - Clostridioides Difficile Infection | Not applicable | Completed | Hellenic Institute for the Study of Sepsis | 153 | 2021-01-26 | 2023-12-12 |
| Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia Tablets, Clarithromycin 500mg - Community-acquired Pneumonia, Sepsis | Phase 3 | Completed | Hellenic Institute for the Study of Sepsis | 278 | 2021-01-25 | 2023-12-12 |
| suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19 Anakinra, Placebo - Covid19 | Phase 3 | Completed | Hellenic Institute for the Study of Sepsis | 606 | 2020-12-23 | 2022-09-06 |
| Bacillus Calmette-guérin Vaccination to Prevent COVID-19 BCG vaccine, Placebo - COVID-19, Virus Diseases | Phase 4 | Completed | Hellenic Institute for the Study of Sepsis | 301 | 2020-05-26 | 2021-05-11 |
| Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early Clarithromycin - COVID-19, Virus Diseases | Phase 2 | Completed | Hellenic Institute for the Study of Sepsis | 90 | 2020-05-06 | 2021-01-11 |
Showing 20 of 32. Sign in to see all of them.
Sepsis (15) · COVID-19 (9) · Infections (7) · Virus Diseases (6) · Community-Acquired Pneumonia (5) · Coronavirus Infections (5) · Pneumonia (3) · Bacterial Infections (2) · Clostridium Infections (2) · Macrophage Activation Syndrome (2) · Bacteremia (1) · Cardiovascular Diseases (1) · Cholangitis (1) · Coronary Disease (1) · Diabetes Mellitus, Type 1 (1)
Interleukin 1 Receptor Antagonist Protein (7) · Clarithromycin (5) · Sodium Chloride (3) · Blood Specimen Collection (2) · Injections (2) · Saline Solution (2) · Tablets (2) · BCG Vaccine (1) · Carbapenems (1) · Environmental Biomarkers (1) · Freeze Drying (1) · Meropenem (1) · Metformin (1) · Solutions (1) · Standard of Care (1)
Greece (32) · Italy (3) · Germany (2) · Belgium (1) · Netherlands (1) · Romania (1) · Spain (1) · Switzerland (1)
Evangelos Giamarellos-Bourboulis, MD, PhD (5) · Antonios Papadopoulos, MD, PhD (4) · Evangelos Giamarellos-Bourboulis, MD,PhD (3) · Evangelos J Giamarellos-Bourboulis, MD, PhD (3) · Apostolos Armaganidis, MD, PhD (2) · Evangelos J Giamarellos-Bourboulis, Professor (2) · Prof. Evangelos Giamarellos-Bourboulis (2) · Anastasia Antoniadou, MD, PhD (1) · Dimitrios Boumpas, MD, PhD (1) · Evagelos Giamarellos-Bourboulis, MD, PhD (1) · Evangelos Giamarellos-Bourboulis (1) · Evangelos Giamarelos-Bourboulis, MD,PhD (1) · Evangelos J Giamarellos-Bourboulis, MD, Phd (1) · Garyfallia Poulakou, MD, PhD (1) · Ioannis Alamanos, MD (1)
PMID 36529030, PMID 41483804, PMID 42704050, PMID 10933646, PMID 14987884, PMID 16003060, PMID 18444850, PMID 20597663, PMID 20610825, PMID 22564837, PMID 22822024, PMID 24183799, PMID 24292991, PMID 26584195, PMID 26903338, PMID 27044546, PMID 27418577, PMID 27856268, PMID 28918754, PMID 30766533, PMID 32757963, PMID 32941801, PMID 33534419, PMID 33682678, PMID 34120316, PMID 34142256, PMID 34363189, PMID 35545011, PMID 35717241, PMID 36384100, PMID 36590789, PMID 36600424, PMID 36867758, PMID 37364721, PMID 38184008, PMID 38321472, PMID 38475786, PMID 38517242, PMID 39418210, PMID 39647797, PMID 40216091, PMID 40583075, PMID 40997264, PMID 41359996, PMID 41427863, PMID 41552367, PMID 41934919, PMID 42624437, PMID 9176497, PMID 9233735
2023 (2), 2025 (2), 2017 (1)